Welcome to the
Biogen Newsroom

Find out how we are pioneering neuroscience to transform lives and support our communities by exploring the latest news releases, Biogen initiatives, company statements and exclusive stories.

Latest News

September 27, 2021
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway

LECANEMAB IS AN ANTI-AMYLOID BETA (Aβ) PROTOFIBRIL ANTIBODY  TOKYO and CAMBRIDGE, Mass, Sep. 28, 2021  - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, “Biogen”) today announced

September 23, 2021
Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative

September 23, 2021  – In 2020, Biogen launched its signature Healthy Climate, Healthy Lives™ initiative, a groundbreaking $250 million, 20-year commitment to address the deeply interrelated issues of climate, health, and equity. Biogen is the first Fortune 500 company to commit to becoming fossil

September 21, 2021
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience

33 early and late-stage clinical programs across modalities and innovative discovery platforms Uniquely positioned to lead in Alzheimer’s disease with ADUHELM ® (aducanumab-avwa) and industry-leading pipeline including Phase 3 lecanemab Potential to transform standard of care in several areas of

See Our Latest Tweets

Biogen Statements
Biogen Statements

See the latest news and statements from Biogen to stay up to date on our progress and learn about new company initiatives.

Annual Report
Annual Report

Review our annual reports to see performance highlights, financials, SEC filings, stock information and more.

Sustainability Report
Sustainability Report: 2020 Year in Review

Learn more about what actions we are taking to deliver on our bold and unwavering commitments to our patients, employees, environment and communities.

Innovation in Alzheimer's

We remain focused on furthering Alzheimer’s disease research and treatment. Explore the latest information, news and stories about Alzheimer’s disease at Biogen.

Alzheimer

The Alzheimer’s Puzzle: Unlocking the Science

From imaging that enables us to see amyloid and tau in the brain and determine whether potential therapeutics reach their targets, to one big leap of faith that antibodies can get into the brain, our scientists are not giving up on solving the Alzheimer’s puzzle.

health
Healthy Climate, Healthy Lives™

Biogen invests $250 million in a 20-year initiative to accelerate action on the greatest challenges of our time: climate, health and equity.

Read More
Diversity
Diversity, Equity and Inclusion

We are committed to building on our culture of inclusion and belonging that reflects the communities where we operate and the patients who we serve.

Read More
Corporate Responsibility

Our Commitment to Corporate Responsibility

Our impact goes beyond our medicines as we strive to improve patient health outcomes, solve social and environmental challenges, and help our employees thrive.

Request Multimedia Resources

For Media Professionals

Access Biogen logos, infographics, images, videos and more. Our media relations team will help you find exactly what you need.

Get Biogen Updates Delivered to Your Inbox

Subscribe to receive news and stories from Biogen that reflect both our dedication to transforming lives through pioneering neuroscience as well as our commitment to our communities.”

Sign Up for Biogen Alerts
Be the first to know about the latest news, updates, events and SEC Filings by signing up for Biogen email alerts.